Analysts Set Nevro Corp. (NYSE:NVRO) Target Price at $21.23

Shares of Nevro Corp. (NYSE:NVRO - Get Free Report) have been assigned an average recommendation of "Hold" from the thirteen ratings firms that are currently covering the company, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating, eleven have given a hold rating and one has given a buy rating to the company. The average 12 month price target among analysts that have updated their coverage on the stock in the last year is $21.23.

A number of equities research analysts have recently issued reports on NVRO shares. StockNews.com raised shares of Nevro from a "sell" rating to a "hold" rating in a report on Friday, March 1st. Royal Bank of Canada cut their price target on shares of Nevro from $18.00 to $16.00 and set a "sector perform" rating for the company in a report on Monday, April 15th. Oppenheimer cut Nevro from an "outperform" rating to a "market perform" rating in a report on Thursday, February 22nd. Robert W. Baird cut their target price on Nevro from $23.00 to $19.00 and set a "neutral" rating for the company in a research note on Thursday, February 22nd. Finally, Mizuho lowered their price target on Nevro from $20.00 to $16.00 and set a "neutral" rating for the company in a report on Thursday, April 11th.

Institutional Trading of Nevro

A number of institutional investors have recently bought and sold shares of NVRO. Assetmark Inc. boosted its stake in Nevro by 30.4% in the fourth quarter. Assetmark Inc. now owns 3,131 shares of the medical equipment provider's stock valued at $67,000 after acquiring an additional 730 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank increased its stake in Nevro by 83.8% in the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 9,970 shares of the medical equipment provider's stock valued at $192,000 after purchasing an additional 4,547 shares during the period. Versor Investments LP raised its holdings in shares of Nevro by 22.9% in the third quarter. Versor Investments LP now owns 11,017 shares of the medical equipment provider's stock valued at $212,000 after buying an additional 2,050 shares during the last quarter. Natixis Advisors L.P. acquired a new stake in shares of Nevro during the third quarter worth about $248,000. Finally, SG Americas Securities LLC acquired a new stake in Nevro during the 3rd quarter worth approximately $274,000. 95.52% of the stock is owned by hedge funds and other institutional investors.

Nevro Price Performance

NVRO traded up $0.38 during trading on Tuesday, hitting $11.53. The company's stock had a trading volume of 482,188 shares, compared to its average volume of 498,429. The firm has a market capitalization of $422.92 million, a price-to-earnings ratio of -4.49 and a beta of 0.96. Nevro has a twelve month low of $10.27 and a twelve month high of $28.89. The business's fifty day simple moving average is $13.21 and its 200 day simple moving average is $16.27. The company has a current ratio of 6.37, a quick ratio of 4.94 and a debt-to-equity ratio of 0.72.

Nevro (NYSE:NVRO - Get Free Report) last released its earnings results on Wednesday, February 21st. The medical equipment provider reported ($0.15) EPS for the quarter, topping analysts' consensus estimates of ($0.50) by $0.35. The business had revenue of $116.18 million during the quarter, compared to analysts' expectations of $115.93 million. Nevro had a negative net margin of 21.69% and a negative return on equity of 30.22%. On average, equities research analysts forecast that Nevro will post -2.54 EPS for the current fiscal year.

Nevro Company Profile

Nevro Corp., a medical device company, engages in the provision of products for patients suffering from chronic pain in the United States and internationally. The company provides HFX spinal cord stimulation (SCS) platform, which includes the Senza SCS implantable pulse generator (IPG) system, an evidence-based neuromodulation system for the treatment of chronic back and leg pain through paresthesia-free 10 kHz therapy, as well as offers Senza II and Senza Omnia SCS IPG systems.